Status:
RECRUITING
Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances
Lead Sponsor:
Distribuidora Biolife SA de CV
Conditions:
Addiction;Drug(S);LSD
Neuroprotective
Eligibility:
MALE
18-50 years
Phase:
NA
Brief Summary
Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption pres...
Detailed Description
Omega 5 (Nano PSO) has been shown to be a powerful antioxidant with neuroprotective and anti-inflammatory effects in various neurological and neurodegenerative diseases. In patients who consume psycho...
Eligibility Criteria
Inclusion
- Patients who are multiple users of methamphetamines, cocaine, and cannabis with or without alcohol and tobacco, and have a history of at least 3 years of consumption.
- Patients who accept informed consent to participate in the protocol.
- Male gender.
- Age between 18-50 years in the withdrawal phase currently in residential treatment
Exclusion
- Individuals under 18 years of age.
- Patients who do not sign the informed consent.
- Discharge of patients prior to the stipulated 6 months, requested by family members.
- Patients with developed or known allergies.
- Patients who are consuming NSAIDs, MAOIs (monoamine oxidase Inhibitor), active chronic inflammatory diseases, or any type of cancer
Key Trial Info
Start Date :
March 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06550167
Start Date
March 15 2024
End Date
March 15 2027
Last Update
August 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Irene Guadalupe Aguilar García PhD.
Guadalajara, Jalisco, Mexico